Mark Buthman Net Worth

The estimated Net Worth of Mark A Buthman is at least $33.4 Million dollars as of 19 November 2015. Mr. Buthman owns over 5,988 units of West Pharmaceutical Services stock worth over $30,039,682 and over the last 21 years he sold WST stock worth over $3,083,366. In addition, he makes $306,787 as Independent Director at West Pharmaceutical Services.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Buthman WST stock SEC Form 4 insiders trading

Mark has made over 31 trades of the West Pharmaceutical Services stock since 2003, according to the Form 4 filled with the SEC. Most recently he sold 5,988 units of WST stock worth $730,536 on 19 November 2015.

The largest trade he's ever made was exercising 99,956 units of West Pharmaceutical Services stock on 30 January 2012 worth over $6,084,322. On average, Mark trades about 5,368 units every 40 days since 2003. As of 19 November 2015 he still owns at least 99,354 units of West Pharmaceutical Services stock.

You can see the complete history of Mr. Buthman stock trades at the bottom of the page.

Mark Buthman biography

Mark A. Buthman serves as Independent Director of the Company. Mr. Buthman retired from Kimberly-Clark Corporation—a global producer of branded products for the consumer, professional and healthcare markets—in December 2015, where he was Executive Vice President and Chief Financial Officer from January 2003 to April 2015. During his 33-year career at Kimberly-Clark, Mr. Buthman held a wide range of leadership roles in finance, strategy and operations, and led or participated in more than 50 acquisitions during his tenure as Chief Financial Officer. Mr. Buthman is a Board member of IDEX Corporation and Vice Chairman of the Board of Directors of Pavillon International.

What is the salary of Mark Buthman?

As the Independent Director of West Pharmaceutical Services, the total compensation of Mark Buthman at West Pharmaceutical Services is $306,787. There are 15 executives at West Pharmaceutical Services getting paid more, with Eric Green having the highest compensation of $6,533,690.

How old is Mark Buthman?

Mark Buthman is 59, he's been the Independent Director of West Pharmaceutical Services since 2011. There are 8 older and 17 younger executives at West Pharmaceutical Services. The oldest executive at West Pharmaceutical Services, Inc. is Patrick Zenner, 73, who is the Independent Chairman of the Board.

What's Mark Buthman's mailing address?

Mark's mailing address filed with the SEC is 3100 SANDERS ROAD, SUITE 301, NORTHBROOK, IL, 60062.

Insiders trading at West Pharmaceutical Services

Over the last 19 years, insiders at West Pharmaceutical Services have traded over $32,829,857 worth of West Pharmaceutical Services stock and bought 19,924 units worth $1,139,950 . The most active insiders traders include Robert F Friel, Paolo Pucci, and Douglas A Michels. On average, West Pharmaceutical Services executives and independent directors trade stock every 40 days with the average trade being worth of $4,786,805. The most recent stock trade was executed by Charles Witherspoon on 19 August 2024, trading 1,029 units of WST stock currently worth $308,700.

What does West Pharmaceutical Services do?

west works side-by-side with healthcare partners from concept to the patient, designing and manufacturing packaging and delivery systems that promote efficiency, reliability and safety. west leads the way with cutting-edge technologies and quality systems, a thorough understanding of global regulatory compliance, and an unmatched knowledge of relevant pharmaceutical product testing, development and packaging. west supports customers from sales, manufacturing, and research and development locations in north and south america, europe, asia and australia.

Complete history of Mr. Buthman stock trades at Idex, Kimberly-Clark, and West Pharmaceutical Services

West Pharmaceutical Services executives and stock owners

West Pharmaceutical Services executives and other stock owners filed with the SEC include:

• Eric Green,
  President, Chief Executive Officer, Director
• Eric M. Green,
  Pres, CEO & Director
• Bernard Birkett,
  Chief Financial Officer, Senior Vice President
• George Miller,
  Senior Vice President, General Counsel, Corporate Secretary
• Bernard J. Birkett,
  Sr. VP & CFO
• Silji Abraham,
  Senior Vice President and Chief Digital and Transformation Officer
• David Montecalvo,
  Senior Vice President, Chief Operating and Supply Chain Officer
• Annette Favorite,
  Chief Human Resource Officer, Senior Vice President
• David A. Montecalvo,
  Sr. VP and Chief Operations & Supply Chain Officer
• Silji Abraham,
  Sr. VP & Chief Technology Officer
• Patrick Zenner,
  Independent Chairman of the Board
• Douglas Michels,
  Independent Director
• Thomas Hofmann,
  Independent Director
• Paula Johnson,
  Independent Director
• William Feehery,
  Independent Director
• Mark Buthman,
  Independent Director
• Myla Lai-Goldman,
  Independent Director
• Paolo Pucci,
  Independent Director
• Deborah Keller Tanner,
  Independent Director
• Chad Winters,
  Chief Accounting Officer, Principal Accounting Officer, Vice President, Controller
• Robert Friel,
  Independent Director
• Cindy Reiss-Clark,
  Senior Vice President of Global Market Units and Commercial Solutions
• Quintin Lai,
  Vice President - Corporate Development, Strategy and Investor Relations
• Eric Resnick,
  Chief Technology Officer, Vice President
• Richard D. Luzzi,
  Sr. VP of HR
• Annette F. Favorite,
  Chief HR Officer & Sr. VP
• Michele Polinsky,
  VP of Global Communications
• Kimberly Banks MacKay,
  Sr. VP, Gen. Counsel & Company Sec.
• Dr. Quintin J. Lai C.F.A., Ph.D.,
  VP of Strategy & Investor Relations
• Daniel Malone,
  Vice President & Controller
• William J Federici,
  VP & CFO
• John H Weiland,
  Director
• Karen Flynn,
  President, America's Region
• Heino Lennartz,
  President Europe
• Anthony Welters,
  Director
• Warwick Bedwell,
  VP Pharma Pkgs Systems Asia Pa
• John E Paproski,
  Vice President-Innovations
• Christopher G Ryan,
  President, PPS, Americas
• Rachael M Bushey,
  VP, Deputy Gen Coun & Corp Sec
• Jeffrey C Hunt,
  VP Pharma Pckg Systems
• John R Gailey,
  VP, Gen. Counsel & Sec.
• Richard D Luzzi,
  VP, Human Resourses
• L Robert Johnson,
  Director
• Michael A Anderson,
  Vice President & Treasurer
• Donald E Jr Morel,
  Chairman of the Board & CEO
• Robert C Young,
  Director
• Donald A Mc Millan,
  President Pharma Systems NA
• Steven A Ellers,
  Pres., Pharma. Systems Div.
• Geoffrey F Worden,
  Director
• John P Neafsey,
  Director
• Joseph E Abbott,
  Corporate Controller
• Dijk Ronald Van,
  President Asia Pacific
• Robert S Hargesheimer,
  President-The Tech Group
• Fabio De Sampaio Doria Filho,
  Pres., Europe & Asia Pacific
• Matthew T Mullarkey,
  Chief Operating Officer
• Robert J Keating,
  Pres., Europe & Asia Pacific
• Jenne K Britell,
  Director
• Herbert L Hugill,
  Pres. of the Americas, Pharma.
• Linda R Altemus,
  VP & Chief Compliance Officer
• Molly Joseph,
  Director
• Deborah L Keller,
  Director
• Stephen H Lockhart,
  Director
• Charles Witherspoon,
  VP & Treasurer
• Kimberly Banks Mac Kay,
  SVP, GC & Corporate Secretary